Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603566 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Pulike Biological Engineering's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulike Biological Engineering Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pulike Biological Engineering's Days Payable distribution charts can be found below:
* The bar in red indicates where Pulike Biological Engineering's Days Payable falls into.
Pulike Biological Engineering Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulike Biological Engineering (SHSE:603566) has a Days Payable of 105.01 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pulike Biological Engineering and its competitors. This is 65% above median its historical median of 63.49. Over the past decade, Pulike Biological Engineering's Days Payable has ranged from 45.15 to 123.08. According to the industry distribution chart, Pulike Biological Engineering ranks #368 out of 702 companies in the Biotechnology industry, placing it in the top 52.4%.
Is Pulike Biological Engineering's Days Payable too high?
Pulike Biological Engineering's current Days Payable of 105.01 is 65% above median its 10-year median of 63.49. Over the past 10 years, this metric has ranged from a low of 45.15 to a high of 123.08. The Biotechnology industry median Days Payable is 113.10. Pulike Biological Engineering's value of 105.01 is 7.2% below this industry median. Based on the distribution chart, Pulike Biological Engineering ranks #368 out of 702 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pulike Biological Engineering has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pulike Biological Engineering's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pulike Biological Engineering ranks #368 out of 702 companies for Days Payable. This places Pulike Biological Engineering in the lower half of its industry. The industry median Days Payable is 113.10. Pulike Biological Engineering's value of 105.01 is 7.2% below this benchmark. Historically, Pulike Biological Engineering's own Days Payable has ranged from 45.15 to 123.08 over the past decade. While the company's 10-year median is 63.49 vs. the industry median of 113.10, Pulike Biological Engineering has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pulike Biological Engineering's current Days Payable of 105.01 is 7.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pulike Biological Engineering and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulike Biological Engineering's current Days Payable is 105.01, which is 65% above median its own 10-year median of 63.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulike Biological Engineering stock overvalued right now?
Based on GuruFocus' analysis, Pulike Biological Engineering (SHSE:603566) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.30, compared to a current price of ¥10.31 — trading 27.9% below its estimated fair value. The current Days Payable is 105.01, which is 65% above median its 10-year median of 63.49 and 7.2% below the Biotechnology industry median of 113.10. Pulike Biological Engineering's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pulike Biological Engineering (SHSE:603566), the current Days Payable is 105.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pulike Biological Engineering (SHSE:603566) Overvalued in 2026?
Based on GuruFocus' analysis, Pulike Biological Engineering stock appears to be undervalued.
The current stock price of ¥10.31 is trading 27.9% below its estimated GF Value™ of ¥14.30.
GuruFocus considers Pulike Biological Engineering to be Modestly Undervalued.
Key valuation signals for SHSE:603566:
Days Payable: 105.01 (65% above median its 10-year median of 63.49)
GF Value™: ¥14.30 vs. price of ¥10.31 (27.9% below fair value)
Industry Position: 7.2% below the Biotechnology median (#368 of 702)
No single metric tells the full story. See the SHSE:603566 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pulike Biological Engineering Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603566 has been successfully added to your 
